We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
- Authors
Matsuo, Hidemasa; Wakita, Tomohiro; Hiramatsu, Hidefumi; Ohmori, Katsuyuki; Kodama, Kumi; Nakatani, Kana; Kamikubo, Yasuhiko; Iwamoto, Shotaro; Kondo, Tadakazu; Takaori‐Kondo, Akifumi; Takita, Junko; Tomizawa, Daisuke; Taga, Takashi; Adachi, Souichi
- Abstract
Keywords: acute megakaryoblastic leukemia; Down syndrome; CLEC12A; TIM3; CD96 EN acute megakaryoblastic leukemia Down syndrome CLEC12A TIM3 CD96 e7 e11 5 12/21/20 20210101 NES 210101 Acute myeloid leukaemia (AML) is a genetically and clinically heterogeneous disease, characterized by expansion of undifferentiated myeloid precursor cells.1 Despite an increased understanding of the biology and therapeutic advances, the outcomes of AML patients remain unsatisfactory. The average CLEC12A-positive cell rate was significantly lower in FAB-M7 cases (10-8%) than that in non-FAB-M7 cases (91-8%, I P i = 2.8E-20; Fig 1C); however, the average TIM3-positive cell rate did not differ significantly between the two groups (67-5% vs. 62-1%, respectively, I P i = 0-66). The average CD96-positive cell rate was also significantly lower in samples from FAB-M7 patients (20-7%) than in those from non-FAB-M7 patients (59-5%, I P i = 0-0002).
- Subjects
ACUTE leukemia; DOWN syndrome; ACUTE myeloid leukemia; CHILD patients
- Publication
British Journal of Haematology, 2021, Vol 192, Issue 1, pe7
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17122